{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:02:09Z","timestamp":1717538529619},"reference-count":46,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.5551\/jat.62141","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T22:06:53Z","timestamp":1614377213000},"page":"451-463","source":"Crossref","is-referenced-by-count":4,"title":["Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP"],"prefix":"10.5551","volume":"29","author":[{"given":"Daiji","family":"Nagayama","sequence":"first","affiliation":[{"name":"Nagayama Clinic"},{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Saiki","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Pharmaceutical Unit, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Pharmaceutical Unit, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Moroi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (Ohashi), Department of Internal Medicine, Faculty of Medicine, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Medical Correction Center in East Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mihama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Tatsuno","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation, 2004; 110: 1061-1068","DOI":"10.1161\/01.CIR.0000140261.58966.A4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368: 1155-1163","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 1999; 84: 413-428","DOI":"10.1016\/S0163-7258(99)00045-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sever PS, Dalhoff B, Poulter NR, Wedel H, Beavers G, Caulfield M, Collins R, Kjeldsen SE, Kristensen A, McInnes GT. Mohsen J, Nieminen M, O\u2019Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet, 2003; 361: 1149-1158","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Arca M, Gaspardone A. Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs, 2007; 67 Suppl 1: 2942","DOI":"10.2165\/00003495-200767001-00004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Saito Y. Pitavastatin: an overview. Atheroscler Suppl, 2011; 12: 271-276","DOI":"10.1016\/S1567-5688(11)70886-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. A 52-week, randomized, open-label, parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101","DOI":"10.1016\/j.clinthera.2008.05.017"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, Shinohara H, Tamura Y. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol, 2008; 125: 136-138","DOI":"10.1016\/j.ijcard.2007.01.040"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N, Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb, 2008; 15: 345-350","DOI":"10.5551\/jat.E581"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302","DOI":"10.1161\/circ.118.suppl_18.S_657-c"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Choi JY, Choi CU, Hwang SY, Kim HS, Jeong MH, KAMIR-NIH Investigators. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol, 2018; 122: 922-928","DOI":"10.1016\/j.amjcard.2018.06.017"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab, 2011; 13: 1047-1055","DOI":"10.1111\/j.1463-1326.2011.01477.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Mita T, Nakayama S, Abe H, Gosho M, Iida H, Hirose T, Kawamori R, Watada H. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig, 2013; 4: 297-303","DOI":"10.1111\/jdi.12032"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 2008; 201: 345-352","DOI":"10.1016\/j.atherosclerosis.2008.02.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, Sato N, Shiba T, Sugimoto H, Fujioka T, Chiba T, Nishizawa K, Usui S, Iwasaki Y, Tatsuno I, Sugi K, Yamasaki J, Yamamura S, Shirai K. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol, 2020; 305: 139-146","DOI":"10.1016\/j.ijcard.2020.01.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Saiki A, Watanabe Y, Yamaguchi T, Ohira M, Nagayama D, Sato N, Kanayama M, Takahashi M, Shimizu K, Moroi M, Miyashita Y, Shirai K, Tatsuno I. CAVI-lowering Effect of Pitavastatin may be Involved in Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. J Atheroscler Thromb, 2021; 28: 1083-1094","DOI":"10.5551\/jat.60343"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nilsson-Ehle P.A, Garfinkel A.S, Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem, 1991; 49: 667-693","DOI":"10.1146\/annurev.bi.49.070180.003315"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Saxena U, Klein M.G, Goldberg I.J. Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci U S A, 1991; 88: 2254-2258","DOI":"10.1073\/pnas.88.6.2254"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta, 1993; 216: 113-123","DOI":"10.1016\/0009-8981(93)90144-S"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15: 1086-1093","DOI":"10.1161\/01.ATV.15.8.1086"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res, 2001; 33: 412-416","DOI":"10.1055\/s-2001-16230"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract, 2007; 76: 93-101","DOI":"10.1016\/j.diabres.2006.08.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Miyashita Y, Shirai K. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract, 2006; 74: 242-248","DOI":"10.1016\/j.diabres.2006.04.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ohira M, Miyashita Y, Ebisuno M, Saiki A, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Shirai K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract, 2007; 78: 34-41","DOI":"10.1016\/j.diabres.2007.02.012"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I. Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes, 2014; 7: 313-319","DOI":"10.2147\/DMSO.S65275"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hitsumoto T, Yoshinaga K, Noike H, Kanai M, Shirai K. Clinical significance of preheparin serum lipoprotein lipase mass in coronary vasospasm. Jpn Circ J, 2001; 65: 539-544","DOI":"10.1253\/jcj.65.539"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, Shirai K. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis, 2000; 153: 391-396","DOI":"10.1016\/S0021-9150(00)00413-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shira K. Effects of body weight reduction on cardio-ankle vascular index (CAVI). Obes Res Clin Pract, 2013; 7: e139-e145","DOI":"10.1016\/j.orcp.2011.08.154"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract, 2002; 56: 181-187","DOI":"10.1016\/S0168-8227(01)00369-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract, 1999; 46: 35-41","DOI":"10.1016\/S0168-8227(99)00063-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12: 163-168","DOI":"10.5551\/jat.12.163"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ohira M, Endo K, Saiki A, Miyashita Y, Terai K, Murano T, Watanabe F, Tatuno I, Shirai K. Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase. Metabolism, 2012; 61: 1452-1460","DOI":"10.1016\/j.metabol.2012.03.010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scand J Clin Lab Invest, 2014; 74: 285-295","DOI":"10.3109\/00365513.2014.882015"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Roberts W.C. The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy. Am. J. Cardiol., 1988; 62: 345-346","DOI":"10.1016\/0002-9149(88)90248-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant, 2013; 48: 452-458","DOI":"10.1038\/bmt.2012.244"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Katsiki N, Reiner \u017d, Reiner ET, Al-Rasadi K, Pirro M, Mikhailidis PD, Sahebkar A. Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opin Pharmacother, 2018; 19: 279-286","DOI":"10.1080\/14656566.2018.1428560"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract, 2011; 65: 1200-1201","DOI":"10.1111\/j.1742-1241.2011.02741.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Nagayama D, Ohira M, Saiki A, Shirai K, Tatsuno I. Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients. Int Heart J, 2014; 55: 337-341","DOI":"10.1536\/ihj.13-377"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kobayashi J, Maruyama T, Masuda M, Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta, 2001; 314: 261-264","DOI":"10.1016\/S0009-8981(01)00701-X"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, Otsuka M, Ito Y, Shirai K. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb, 2004; 11: 341-347","DOI":"10.5551\/jat.11.341"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract, 2010; 64: 1796-1801","DOI":"10.1111\/j.1742-1241.2010.02399.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. J Atheroscler Thromb, 2015; 22: 1158-1171","DOI":"10.5551\/jat.29520"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond), 2005; 29: 1115-1120","DOI":"10.1038\/sj.ijo.0803009"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci, 2002; 71: 2403-2412","DOI":"10.1016\/S0024-3205(02)02038-6"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid parameters are independently associated with cardio-ankle vascular index (CAVI) in healthy Japanese subjects. J Atheroscler Thromb, 2018; 25: 621-633","DOI":"10.5551\/jat.42291"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/4\/29_62141\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:28:09Z","timestamp":1715232489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/4\/29_62141\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.62141","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"62141"}}